从阿维菌素获得诺贝尔奖到中国创造

Avermectin, from winning the Nobel Prize to “innovation in China”

摘要:

纵观世界历史,大国崛起无不伴随着科技的兴起和机制体制的突破。来自大自然的天然产物对于人类的健康起到非常重要的作用,从抗肿瘤明星分子紫杉醇到挽救了无数人生命的抗感染药物青霉素,从治疗代谢疾病到营养保健,都离不开天然产物。此外,还有大量天然产物资源没有被开发过。而随着阿维菌素的发现者Satoshi Ōmura教授和William C. Campbell博士,及青蒿素的发现者屠呦呦研究员因为这两种天然产物在治疗寄生虫感染病和疟疾上的应用而获得2015年诺贝尔生理与医学奖后,天然产物有望迎来其发展的第二个黄金时代。我国是世界工厂也是天然药物的资源大国,为了实现产业升级,弯道超车,实现大国崛起的中国梦,我国科学家在“十二五”期间围绕着天然产物的高产和创新两大主题开展了富有成效的合成生物学研究。阿维菌素是由阿维链霉菌产生的高效低毒生物杀虫剂,其原料产能占国际市场的100%。但我国原有生产菌株的单位发酵产量较低,高消耗、高污染、片面追求生产规模的粗放型发展模式已经成了阻碍低碳经济持续高速发展的瓶颈。如何从根本上解决问题,提高生产菌株的单位发酵产量和原料利用率,降低能耗和生产成本,减少环境污染,是促进我国从“发酵大国”向“发酵强国”转变的关键。本文以阿维菌素为例,综述其基础研究的技术发展,特别是中国科学院微生物研究所引入合成生物学技术,将阿维菌素的单位产量提高了1000倍,至9 g/L,在内蒙古新威远与阿维菌素产业联盟的公司应用,迫使默克公司全面退出阿维菌素历史舞台,从而引领产业迅速发展的过程,为我国其它天然产物生物制造品种的改良提供思路和方法。

Abstract:

The uprise of the superpower nations is always accompanied by the breakthrough and advances of technologies and innovations in the history. Natural products play very important role in human health, such as anticancer molecular taxol, anti-infection drug artemisinin that save a lot of lives, metabolic disease treatment, nutrition and health care. However, more has never been explored. With the 2015 Nobel Prize in Physiology or Medicine awarded to William C. Campbell, Satoshi Ōmura, and Youyou Tu for the discovery of avermectins and artemisinin respectively, the second “Golden age” in the development of natural product is dawning. China is a “world factory” and natural drugs-rich country, but how to upgrade and advance the industry and realize the China dream? Avermectins, produced by Streptomyces avermitilis, are pesticide with high efficiency and low levels of side effects. However, the low producer and expensive development pattern of high consumption, high contamination is not sustainable. Solving the problem, increasing the production and utilization of raw material, reducing the energy consumption and cost of production, decreasing environmental pollution are key to transform China into a power house. In this paper, we case-study avermectins to review the industry development driven by fundamental research. Institute of Microbiology, Chinese Academy of Sciences increased the production of avermectin 1000 folds to 9 g/L, which out licensed to new Veyong biochemical Ltd and avermectin Coalitions. As a result, Merck Sharp and Dohme ceased the manufacture of avermectins. The success also shed lights on the improvement of other natural product drugs in China.